SCHEMBL8960223

SCHEMBL8960223

CCNC(=N)NC(=N)Nc1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CNR1 P21554 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
EPHX1 P07099 1/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14577808 0.87 LMNA (0.49) LMNASMN1; SMN2CNR1MEN1KMT2A
SCHEMBL903037 0.86 POLB (0.41) LMNASMN1; SMN2CNR1MEN1KMT2A
SCHEMBL11037053 0.86 CNR1 (0.47) LMNASMN1; SMN2CNR1MEN1KMT2A
Hydrochloric Acid SCHEMBL11882877 0.85 LMNA (0.48) LMNASMN1; SMN2CNR1MEN1KMT2A
SCHEMBL11236184 0.85 NPC1 (0.50) LMNASMN1; SMN2CNR1MEN1KMT2A
SCHEMBL7940916 0.84 POLB (0.44) SMN1; SMN2MEN1KMT2AALDH1A1TDP1
SCHEMBL10015687 0.84 SMN1; SMN2 (0.61) LMNASMN1; SMN2CNR1MEN1KMT2A
Hydrochloric Acid SCHEMBL13584911 0.83 NPC1 (0.48) LMNASMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL13400831 0.83 SMN1; SMN2 (0.56) LMNASMN1; SMN2ALDH1A1EPHX1
Chlorhexidine SCHEMBL1898352 0.83 LMNA (0.49) LMNASMN1; SMN2CNR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149042-B2 Antiseptic solution of di(4-chloro-phenyldiguanido) compound and process therefor MEDICHEM, S.A. (ES) 2015-10-06 US disclosed
US-9149042-B2 Antiseptic solution of di(4-chloro-phenyldiguanido) compound and process therefor MEDICHEM, S.A. (ES) 2015-10-06 US disclosed
US-20120238635-A1 Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound and Process Therefor COMBINO PHARM, S.L. (ES) 2012-09-20 US disclosed
US-20120237452-A1 Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound And Process Therefor COMBINO PHARM, S.L. (ES) 2012-09-20 US disclosed
US-20120238635-A1 Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound and Process Therefor COMBINO PHARM, S.L. (ES) 2012-09-20 US disclosed
US-20120237452-A1 Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound And Process Therefor COMBINO PHARM, S.L. (ES) 2012-09-20 US disclosed
US-8188068-B2 Bridged polycyclic compound based compositions for coating oral surfaces in pets ALLACCEM, INC. (US) 2012-05-29 US disclosed
US-8153618-B2 Bridged polycyclic compound based compositions for topical applications for pets ALLACCEM, INC. (US) 2012-04-10 US disclosed
US-20100098659-A1 COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS REVALESIO CORPORATION (US) 2010-04-22 US disclosed
US-20100098659-A1 COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS REVALESIO CORPORATION (US) 2010-04-22 US disclosed
US-20100016270-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS ALLACCEM, INC. 2010-01-21 US disclosed
US-20090054528-A1 Bridged polycyclic compound based compositions for coating oral surfaces in pets ALLACCEM, INC. 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054528-A1 Bridged polycyclic compound based compositions for coating oral surfaces in pets PAICS, SLC16A8, CAD LMNA 2168/4885SMN1; SMN2 1523/4885CNR1 471/4885
US-20100016270-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS PCSK9, HMGCR, CETP LMNA 234/4885SMN1; SMN2 1707/4885CNR1 769/4885
US-20120238635-A1 Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound and Process Therefor QDPR, DDT, SLC6A11 LMNA 4870/4885SMN1; SMN2 4736/4885CNR1 657/4885
US-20120237452-A1 Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound And Process Therefor QDPR, DDT, SLC6A11 LMNA 4870/4885SMN1; SMN2 4736/4885CNR1 657/4885
US-20100098659-A1 COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS MMP9, MMP14, MMP10 LMNA 373/4885SMN1; SMN2 104/4885CNR1 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.